ABS-CBN lost P1.13 billion in the July to September quarter of 2026, a smaller deficit than a year earlier, even as its nine-month loss widened and a planned P6-billion capital infusion moved closer to center stage. Revenues for the quarter rose 4.6 percent to P3.63 billion.
The results explain why CBN is back in focus now: the company is trying to shore up its balance sheet while still carrying heavy debt and loan maturities that fall on Nov. 20 and Nov. 30. It expects to recognize a significant capital infusion within the fourth quarter, with I&C Holdings Corp. committing P3.5 billion to the transaction and the Lopez family and new investors also part of the broader plan.
For the first nine months of 2026, ABS-CBN's loss widened 32 percent to P2.96 billion, while revenues slipped 11 percent to P10.52 billion. The decline was partly driven by the absence of political advertising from the 2025 midterm elections and continued weakness in the cable business, both of which weighed on the company even as its content production and distribution arm generated P8.96 billion in revenue.
That business remained the larger engine inside the company, but it was not enough to offset the drag from other parts of the operation. Content production and distribution revenue fell 2 percent, and the segment posted a wider P2.03-billion loss after sales increased 6 percent when election advertising booked last year was stripped out of the comparison.
The sharper strain sits elsewhere. Cable and broadband revenues plunged 41 percent to P1.55 billion, and losses in that segment widened to P923 million. At the same time, ABS-CBN's cash reserves rose to P2.84 billion from P1.03 billion at the start of 2026, and cash generated from operations reached P2.93 billion during the nine months, reversing a P1.76-billion outflow a year earlier.
But that improvement did not come mainly from stronger earnings. Much of the cash flow improvement came from higher amounts owed to suppliers and other creditors rather than profits, while the company also paid P753 million in interest during the period. Its liabilities stood at P36.92 billion as of September against assets of P34.91 billion, leaving negative shareholder equity of about P2 billion and a P14.5-billion gap between short-term liabilities and assets.
That is why the planned infusion matters more than the quarterly bounce in revenue. The company says the capital injection should address the negative equity position, but the balance sheet pressure remains real until the money lands. If the fourth-quarter infusion arrives as expected, it should ease the immediate strain; if it does not, the loan deadlines at the end of November will test how much room the company still has left.
